EBRD Allocates Up to €20 Million to Expand Pharmaceutical Production in Uzbekistan

Tashkent, Uzbekistan (UzDaily.com) — The European Bank for Reconstruction and Development (EBRD) is supporting the development of domestic pharmaceutical production in Uzbekistan by facilitating the expansion of its long-standing client, Samarkand England Eco-Medical (SEEM).

The bank is providing a loan of up to €20 million to SEEM and its affiliated entity, Bayan Medical. These companies specialize in the production of intravenous solutions—including sodium chloride, glucose, and amino acids—as well as generic and specialized medicines in tablet and capsule forms.

The funds will be used to acquire new production lines for SEEM, including facilities for intravenous solutions and antibiotics in glass ampoules, syrups and suspensions, medical water, nasal sprays, suppositories, and ointments. The financing will also allow Bayan Medical to modernize its production capacities to improve energy efficiency. In particular, the company will be able to purchase an ampoule production line using Blow-Fill-Seal (BFS) technology and other specialized equipment. Both companies will also have the opportunity to optimize their balance sheet structures.

The project is expected to increase the share of local pharmaceutical production in a country where around 75% of medical products are still imported. The initiative aims to further localize and technologically modernize the sector.

On the social side, Bayan Medical will implement an internship program for university graduates, provide specialized training for employees, and create additional employment opportunities for people with disabilities.

Since its operations began in Uzbekistan, the EBRD has invested approximately US$6.9 billion (€5.8 billion) across 205 projects, with a significant portion of funds directed to support the private sector. Over the past six years, Uzbekistan has remained the largest recipient of the bank’s financing in Central Asia.